论文部分内容阅读
目的:探讨阿德福韦酯(ADV)治疗慢性乙型肝炎的临床价值。方法:本次医学研究选取2011年1月-2014年1月收治的慢性乙型肝炎患者100例为观察对象,随机将其分为第一组和第二组,第一组全程接受阿德福韦酯治疗,第二组分别接受安慰剂和阿德福韦酯治疗,比较两组患者的临床疗效。结果:第一组患者治疗4周、12周血清乙型病毒性肝炎-脱氧核糖核酸(HBV-DNA)水平完全和部分抑制情况优于第二组,差异有统计学意义(P<0.05),两组患者治疗24周、36周、48周后血清HBV-DNA水平完全和部分抑制情况比较,差异无统计学意义(P>0.05)。结论:阿德福韦酯治疗慢性乙型肝炎,有助于控制患者病情的进一步恶化,临床价值较高。
Objective: To investigate the clinical value of adefovir dipivoxil in the treatment of chronic hepatitis B. Methods: This study selected 100 patients with chronic hepatitis B who were admitted to our hospital from January 2011 to January 2014. The patients were randomly divided into the first group and the second group. The first group received Adelaide Weixi treatment, the second group were treated with placebo and adefovir dipivoxil, the clinical efficacy of two groups were compared. Results: The levels of HBV-DNA in the first group were better than those in the second group after treatment for 4 weeks and 12 weeks, with significant difference (P <0.05) There was no significant difference between the two groups in the complete and partial inhibition of serum HBV-DNA levels after 24 weeks, 36 weeks and 48 weeks of treatment (P> 0.05). Conclusion: adefovir dipivoxil treatment of chronic hepatitis B, helps to control the patient’s condition further deterioration, high clinical value.